Taysha Gene Therapies, Inc. Common Stock (TSHA)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Taysha Gene Therapies, Inc. Common Stock (TSHA) is listed on Nasdaq, where it has traded since September 24, 2020.
- Listed On
- Nasdaq
- Listed Since
- September 24, 2020
- Employees
- 99
- Market Cap
- $1.6B
About Taysha Gene Therapies, Inc. Common Stock
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 201 institutions reported holding TSHA, with 299.1 million shares worth $2.1 billion in aggregate. The largest reported holder was Avoro Capital Advisors, with 23.9 million shares worth $162.7 million. Of the 5 largest holders listed below, 4 added shares and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Avoro Capital Advisors | 23,888,888 | $163M | Added 10.09% |
| RA Capital Management, | 23,555,648 | $160M | Unchanged |
| Goldman Sachs | 22,713,118 | $155M | Added 1.54% |
| BlackRock | 20,691,927 | $141M | Added 12.67% |
| Vestal Point Capital | 19,415,000 | $132M | Added 7.86% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is TSHA?
Taysha Gene Therapies, Inc. Common Stock (TSHA) is listed on Nasdaq, where it has traded since September 24, 2020.
Who are the largest institutional holders of TSHA?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of TSHA were Avoro Capital Advisors, RA Capital Management, and Goldman Sachs.
How many institutions own TSHA?
201 institutions reported a position in TSHA for the quarter ended June 30, 2026, worth $2.1 billion in total.
Did institutions buy or sell TSHA last quarter?
Of the 5 largest reported holders, 4 added shares and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for TSHA.
Every reported institutional holder, plus insider and congressional trades in TSHA, on SentiSense.